JP2007230869A - アルドステロン受容体拮抗剤 - Google Patents

アルドステロン受容体拮抗剤 Download PDF

Info

Publication number
JP2007230869A
JP2007230869A JP2004111397A JP2004111397A JP2007230869A JP 2007230869 A JP2007230869 A JP 2007230869A JP 2004111397 A JP2004111397 A JP 2004111397A JP 2004111397 A JP2004111397 A JP 2004111397A JP 2007230869 A JP2007230869 A JP 2007230869A
Authority
JP
Japan
Prior art keywords
group
optionally substituted
reference example
methyl
dihydropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004111397A
Other languages
English (en)
Japanese (ja)
Inventor
Masaji Fukumoto
正司 福本
Taiichi Oura
泰一 邑楽
Junichi Sakamoto
潤一 坂本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP2004111397A priority Critical patent/JP2007230869A/ja
Priority to PCT/JP2005/006976 priority patent/WO2005097118A1/fr
Publication of JP2007230869A publication Critical patent/JP2007230869A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2004111397A 2004-04-05 2004-04-05 アルドステロン受容体拮抗剤 Withdrawn JP2007230869A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2004111397A JP2007230869A (ja) 2004-04-05 2004-04-05 アルドステロン受容体拮抗剤
PCT/JP2005/006976 WO2005097118A1 (fr) 2004-04-05 2005-04-04 Antagonistes des récepteurs d'aldostérone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004111397A JP2007230869A (ja) 2004-04-05 2004-04-05 アルドステロン受容体拮抗剤

Publications (1)

Publication Number Publication Date
JP2007230869A true JP2007230869A (ja) 2007-09-13

Family

ID=35124825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004111397A Withdrawn JP2007230869A (ja) 2004-04-05 2004-04-05 アルドステロン受容体拮抗剤

Country Status (2)

Country Link
JP (1) JP2007230869A (fr)
WO (1) WO2005097118A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502753A (ja) * 2005-07-22 2009-01-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト ４−クロメノニル−１，４−ジヒドロピリジン類およびそれらの使用
JP2009502754A (ja) * 2005-07-22 2009-01-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト ４−クロメノニル−１，４−ジヒドロピリジンカルボニトリル類およびそれらの使用
JP2011506440A (ja) * 2007-12-14 2011-03-03 メルク・シャープ・エンド・ドーム・コーポレイション 鉱質コルチコイド受容体調節剤
JP2012522006A (ja) * 2009-03-26 2012-09-20 グプタ，アジャイ 腎疾患の治療のための組成物及び方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DE102006026585A1 (de) * 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung
DE102006044696A1 (de) 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
CA2667966C (fr) 2006-10-31 2011-08-02 Pfizer Products Inc. Composes de pyrazoline en tant qu'antagonistes des recepteurs mineralocorticoides
SG177200A1 (en) * 2006-12-14 2012-01-30 Bayer Schering Pharma Ag Dihydropyridine derivatives useful as protein kinase inhibitors
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
WO2011141456A1 (fr) 2010-05-10 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pour le traitement de l'accumulation de fluides dans et/ou sous la rétine
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CA2854252C (fr) 2011-11-24 2016-11-29 Lipidart Kutato Fejleszto Es Tanacsado Kft. Derives de 1,4-dihydropyridine ayant une activite modulant hsp
CN109721596B (zh) * 2017-10-27 2020-12-18 广东东阳光药业有限公司 苯基取代的二氢吡啶类化合物及其用途
CN109721536B (zh) * 2017-10-27 2020-11-24 广东东阳光药业有限公司 苯基取代的稠合三环类化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1117117A (fr) * 1978-10-10 1982-01-26 Fujisawa Pharmaceutical Co., Ltd. Derives de la 2-methyl-dihydropyridine, methodes de preparation, et composition pharmaceutique de ces derives
JPS6210087A (ja) * 1985-07-03 1987-01-19 Shionogi & Co Ltd ４，７−ジヒドロチエノ〔２，３−ｂ〕ピリジン誘導体，その製造法および循環器系疾患治療剤
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
DE3711991A1 (de) * 1987-04-09 1988-10-20 Bayer Ag Dihydropyridinamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502753A (ja) * 2005-07-22 2009-01-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト ４−クロメノニル−１，４−ジヒドロピリジン類およびそれらの使用
JP2009502754A (ja) * 2005-07-22 2009-01-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト ４−クロメノニル−１，４−ジヒドロピリジンカルボニトリル類およびそれらの使用
JP2011506440A (ja) * 2007-12-14 2011-03-03 メルク・シャープ・エンド・ドーム・コーポレイション 鉱質コルチコイド受容体調節剤
JP2012522006A (ja) * 2009-03-26 2012-09-20 グプタ，アジャイ 腎疾患の治療のための組成物及び方法

Also Published As

Publication number Publication date
WO2005097118A1 (fr) 2005-10-20

Similar Documents

Publication Publication Date Title
JP7337883B2 (ja) 乳酸脱水素酵素の小分子阻害剤及びその使用方法
AU755498B2 (en) 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
WO2005097118A1 (fr) Antagonistes des récepteurs d'aldostérone
KR100518142B1 (ko) 혈당저하 및 지질혈저하 활성을 갖는 5-원ｎ-헤테로고리형 화합물
JP4310109B2 (ja) ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
WO2006085685A1 (fr) Dérivé de pyrazole
KR102530580B1 (ko) 오렉신―１ 수용체의 억제제로서의 치료 화합물
US20090325956A1 (en) Aromatic amine derivative and use thereof
CN104755465A (zh) 杂环化合物
EP1835934A2 (fr) Modulateurs d'enzymes et traitements
TW202142538A (zh) 雜環ｇｌｐ－１促效劑
CA2476162A1 (fr) Inhibiteur de jnk
WO2006070943A1 (fr) Derive condense d'imidazole et applications de ce dernier
CN101365696A (zh) 作为类固醇激素核受体调节剂的化合物和组合物
WO2005090328A1 (fr) Composition hétérocyclique et son utilisation
BG99879A (bg) Инхибитори на нiv реверсивна транскриптаза
WO2016051193A1 (fr) Composés utiles en tant que modulateurs du facteur 1 de stimulation de colonies
KR20090031605A (ko) 신규한 피리딘 유사체
NO873650L (no) Dihydropyridinderivater.
JP2898256B2 (ja) 特定の４−アリール−５−カルバモイル−１，４−ジヒドロピリジンを含む医薬組成物
CZ364698A3 (cs) 2,4-diaminopyrimidinové deriváty
WO2004089937A1 (fr) Derive heterocyclique a sept elements
TW202229273A (zh) 稠合雜芳基化合物及其作為CaMKII抑制劑之用途
JP3012338B2 (ja) アリールおよびヘテロアリールアルコキシナフタレン誘導体
WO2005014576A1 (fr) Derive d'isoquinoline, procede permettant de produire ce derive, et utilisation de ce derive

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20070904